ERDERA Clinical Trial Call 2026 – Pre-announcement

Pre-announcement describing scope, eligibility and indicative timeline for the ERDERA Clinical Trial Call 2026, expected to open on 1 July 2026.

This pre-announcement outlines the upcoming ERDERA Clinical Trial Call 2026 (ECTC), expected to open on 1 July 2026, to support multinational, GCP-compliant Phase I, Phase I/II and Phase II interventional clinical trials in rare diseases.

It summarises priority areas, eligible applicants, eligible interventions (including small molecules, ATMPs and biologics), expected eligible countries and an indicative multi-stage application process, including an information webinar on 6 July 2026 (15:00–17:00 CEST).

Acces this publication

publication

ERDERA clinical trial call

Year of publication

2026

Author

European Rare Diseases Research Alliance (ERDERA)

You might also be interested in

ERDERA Knowledge Exchange Meeting

ERDERA Knowledge Exchange Meeting on Drug Repurposing for Rare Diseases

November 25 - November 26
Discover practical pathways to repurpose medicines for rare diseases, exchange experiences and best practices between underrepresented and high-performing countries, and build new partnerships at the ERDERA Knowledge Exchange Meeting in Riga on 25-26 November.
Journée nationale FrBioNet

ERDERA connects rare disease research and biobanking at FrBioNet’s first national event

ERDERA contributed to the first Journée nationale FrBioNet, bringing a European rare disease perspective to discussions with the French biobanking community.
ERDERA - World Orphan Drug Congress - JVDPhotography-40

Can AI deliver for rare diseases? ERDERA brings the debate to WODC Europe

ERDERA will return to the World Orphan Drug Congress Europe with a booth and an interactive pre-conference workshop examining where artificial intelligence can support rare disease research and therapeutic development, and where human expertise remains essential.
Re(ACT) 2027+ (Courier) icones_page-0001

RE(ACT) Congress 2027

March 10 - March 12
Building on the legacy of the RE(ACT) Congress series (now reaching its ninth edition), RE(ACT) continues to serve as a meeting point for scientific innovation and real-world impact.

ERDERA Search